Patents Assigned to FARMALIDER, S.A.
  • Compound inhibiting activation of the enzyme Erk 1/2 to be used in the treatment of neurodegenerative illnesses
    Patent number: 9000047
    Abstract: The present invention relates to a compound of formula (I) for use as a medicine, in particular for use in the treatment of diseases mediated by the actvation of the protein kinase Erk1/2, such as neurogenerative illnesses like Alzheimer's and related dementia, epilepsy, Parkinson's disease, Huntington's disease, or stroke, and likewise relates to the pharmaceutical compositions containing said compound. The compound of formula (I) effectively inhibits the activation of the enzyme Erk1/2 induced by the tissue plasminogen activator (TPA) and also effectively inhibits the apoptosis generated by the ?-amyloid peptide.
    Type: Grant
    Filed: May 24, 2010
    Date of Patent: April 7, 2015
    Assignee: Farmalider, S.A.
    Inventors: Pilar Navarro Medrano, Elisabet Gregori Puigjane, Marisol Montolio Del Olmo, Ana Jimenez Redondo, Jordi Mestres Lopez
  • Compound Inhibiting Activation of the Enzyme ERK 1/2 To Be Used In The Treatment Of Neurodegenerative Illnesses
    Publication number: 20130065966
    Abstract: The present invention relates to a compound of formula (I) for use as a medicine, in particular for use in the treatment of diseases mediated by the actvation of the protein kinase Erk1/2, such as neurogenerative illnesses like Alzheimer's and related dementia, epilepsy, Parkinson's disease, Huntington's disease, or stroke, and likewise relates to the pharmaceutical compositions containing said compound. The compound of formula (I) effectively inhibits the activation of the enzyme Erk1/2 induced by the tissue plasminogen activator (TPA) and also effectively inhibits the apoptosis generated by the ?-amyloid peptide.
    Type: Application
    Filed: May 24, 2010
    Publication date: March 14, 2013
    Applicant: FARMALIDER, S.A.
    Inventors: Pilar Navarro Medrano, Elisabet Gregori Puigjane, Marisol Montolio Del Olmo, Ana Jimenez Redondo, Jordi Mestres Lopez